BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1415 related articles for article (PubMed ID: 18424269)

  • 1. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
    Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
    Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
    Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
    Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis in liver transplantation recipients after hepatitis B virus recurrence.
    Sun LY; Zhu ZJ; Qu W; Sun XY; Rao W; Liu Y
    Hepatogastroenterology; 2014 Oct; 61(135):2047-51. PubMed ID: 25713909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study.
    Xie SB; Zhu JY; Ying Z; Zeng LJ; Chao M; Lu MQ
    Transplantation; 2010 Oct; 90(7):786-90. PubMed ID: 20703179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B prophylaxis using lamivudine and individualized low-dose hepatitis B immunoglobulin in living donor liver transplantation.
    Jiang L; Yan L; Wen T; Li B; Zhao J; Yang J; Xu M; Wang W
    Transplant Proc; 2013; 45(6):2326-30. PubMed ID: 23953544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
    Singer GA; Zielsdorf S; Fleetwood VA; Alvey N; Cohen E; Eswaran S; Shah N; Chan EY; Hertl M; Fayek SA
    Transplant Proc; 2015 Mar; 47(2):478-84. PubMed ID: 25769595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
    Hosaka T; Suzuki F; Kobayashi M; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Liver Int; 2010 Nov; 30(10):1461-70. PubMed ID: 20840396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBV recurrence lowered by lamivudine/HBIG combination therapy in liver transplant patients: ten-year experience.
    Yuan CH; Xiu DR; Jiang B; Li ZF; Li L; Song SB; Zhang TL
    Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):149-53. PubMed ID: 23558068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
    Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
    Angus PW; Patterson SJ; Strasser SI; McCaughan GW; Gane E
    Hepatology; 2008 Nov; 48(5):1460-6. PubMed ID: 18925641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
    Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection.
    Franchello A; Ghisetti V; Marzano A; Romagnoli R; Salizzoni M
    Liver Transpl; 2005 Aug; 11(8):922-8. PubMed ID: 16035057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation.
    Lee EC; Kim SH; Lee SD; Park H; Lee SA; Park SJ
    World J Gastroenterol; 2016 Apr; 22(14):3803-12. PubMed ID: 27076765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation.
    Saab S; Yeganeh M; Nguyen K; Durazo F; Han S; Yersiz H; Farmer DG; Goldstein LI; Tong MJ; Busuttil RW
    Liver Transpl; 2009 Nov; 15(11):1525-34. PubMed ID: 19877207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.
    Chung GE; Kim W; Lee JH; Kim YJ; Yoon JH; Lee JM; Lee JY; Kim SH; Kim D; Lee HS
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1638-45. PubMed ID: 22011297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
    Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
    World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.